With the growing prosperity of the global biopharmaceutical market and rapid technological advancement, Chinese medical products have emerged as a force in the international market due to their high cost-effectiveness and unique technical advantages. Strong government support and globalization trends have created unprecedented favorable conditions for domestic medical products to go global. Among them, the License-out model dominates in drug exports, while medical device exports rely more on registration or acquisition models.
In recent years, Chinese pharmaceutical companies have actively integrated into the global BD transaction tide, not only promoting the research and development process of innovative drugs but also accelerating global sharing and value maximization of technology. In 2023, Chinese innovative drugs and medical devices have reached a high point of export. Many local innovative pharmaceutical companies have licensed their products to international pharmaceutical giants at highly competitive prices, setting new highs in both the volume and amount of License-out transactions; at the same time, several domestic drugs have successfully obtained marketing approvals from overseas regulatory agencies such as the FDA. Medical device exports have also reached a new milestone, marking that the internationalization pace of China's medical device industry is accelerating.
Against this backdrop, Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') has joined hands with Jintiancheng, Haitong Securities, and LeadLeo to jointly release the '2024 China Innovative Drugs and Medical Devices Export Trends and Strategies White Paper', which conducts an in-depth discussion on topics related to BD transactions, strategies and experiences, as well as legal risks during the export process.
